May Daher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
May Daher has a total of 507 co-authors. Here are the top co-authors by number of shared publications:
- Katayoun Rezvani
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Institute for Cell Therapy Discovery and Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
57 shared publications - Rafet Basar
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA
50 shared publications - Sunil Acharya
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
45 shared publications - Elizabeth J. Shpall
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
43 shared publications - Paul Lin
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
41 shared publications - Ana Karen Nunez Cortes
Institute for Cell Therapy Discovery and Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX
40 shared publications
Latest Publications
- 1 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (9) , 1727-1729
Mitochondrial Complex I at the Crossroads of NK cell Dysfunction in Glioblastoma
Summary: Zhou and colleagues identify mitochondrial complex I activity, mediated through NDUFA9, as a critical determinant of natural killer (NK) cell metabolic fitness and antitumor function in glioblastoma. Their study links impaired oxidative phosphorylation to glutamine dependence, epigenetic repression of effector programs, and loss of NK cell activity, highlighting mitochondrial fitness as an actionable axis for improving cellular immunotherapy in solid tumors. See related article by Zhou et al., p. 1924
- 1 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (9) , 1727-1729
Mitochondrial Complex I at the Crossroads of NK cell Dysfunction in Glioblastoma
Summary: Zhou and colleagues identify mitochondrial complex I activity, mediated through NDUFA9, as a critical determinant of natural killer (NK) cell metabolic fitness and antitumor function in glioblastoma. Their study links impaired oxidative phosphorylation to glutamine dependence, epigenetic repression of effector programs, and loss of NK cell activity, highlighting mitochondrial fitness as an actionable axis for improving cellular immunotherapy in solid tumors. See related article by Zhou et al., p. 1924
- Open Access
- 25 June 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (7) , 102881
Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions
- 25 June 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (7) , 102881
Open AccessAdvancing CAR-NK cell therapy in solid tumors: Current landscape and future directions
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 1 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
CAR27-ζ NK cell serial killing against Raji cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 1 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
CAR27-ζ NK cell serial killing against Raji cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
CAR27-28ζ NK cells show polyfunctionality.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
CAR27-28ζ NK cells show polyfunctionality.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
(Related to Fig.6G) The list of differentially abundance proteins between CAR27-ζ vs. CAR27-28.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
(Related to Fig.6G) The list of differentially abundance proteins between CAR27-ζ vs. CAR27-28.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
CD28 co-stimulation enhances phosphorylation of the CAR CD3ζ signaling endodomain.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
CD28 co-stimulation enhances phosphorylation of the CAR CD3ζ signaling endodomain.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
In vitro characterization of the CAR27 constructs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
In vitro characterization of the CAR27 constructs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
In vivo antitumor activity of CAR27-expressing NK cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
In vivo antitumor activity of CAR27-expressing NK cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
Expression of CD70 at the protein and mRNA levels in different tumor types.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
Expression of CD70 at the protein and mRNA levels in different tumor types.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
(Related to Fig.6F) The list of differentially abundance proteins between CAR27-ζ vs. CAR27-28ζ.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
(Related to Fig.6F) The list of differentially abundance proteins between CAR27-ζ vs. CAR27-28ζ.